The effect of anticoagulant drugs on cancer

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 8, 2004, Pages 1263-1265

  Falanga, Anna ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTIVITAMIN K; DALTEPARIN; FIBRIN; FIBRIN DEGRADATION PRODUCT; HEPARIN; HEPARIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; THROMBIN; THROMBOPLASTIN; WARFARIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD CLOTTING; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CELL TRANSFORMATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; HUMAN; IN VITRO STUDY; LONG TERM CARE; LUNG SMALL CELL CANCER; META ANALYSIS; METASTASIS; MONOTHERAPY; MORTALITY; NONHUMAN; OSTEOPOROSIS; PELVIS CANCER; PRIORITY JOURNAL; PROGNOSIS; THROMBOEMBOLISM; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 13244299063     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00868.x     Document Type: Article

References (17)

1. Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 2001; 102: V215-V224.
2. Falanga A, Marchetti M, Vignoli A, Balducci D. Clotting mechanisms and cancer: implications in thrombus formation and tumor progression. Clin Adv Hematol Oncol 2003; 1: 673-8.
3. Zacharski LR, Ornstein DL. Heparin and cancer. Thromb Haemost 1998; 80: 10-23.
4. Colucci M, Delaini F, de Bellis Vitti G, Locati D, Poggi A, Semeraro N, Donati MB. Warfarin inhibits both procoagulant activity and metastatic capacity of Lewis lung carcinoma cells. Role of vitamin K deficiency. Biochem Pharmacol 1983; 32: 1689-91.
5. Michaels L. Cancer incidence and mortality in patients having anticoagulant therapy. Lancet 1964; 22: 832-5.
6. Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ Jr, Forcier RJ, Edwards R, Headley E, Kim SH, O'Donnell JR, O'Dell R, Tornyos K, Kwaan HC. Effect of warfarin on survival in small cell carcinoma of the lung. JAMA 1981; 245: 831-5.
7. Smorenburg SM, Vink R, Otten HM, Swaneveld F, Buller HR. The effects of vitamin K-antagonists on survival of patients with malignancy: a systematic analysis. Thromb Haemost 2001; 86: 1586-7.
8. Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C, Mornet M, Brun J, Hurdebourcq JP, Lemarie E. Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer 1994; 74: 38-4.
9. Smorenburg SM, Hettiarachchi RJ, Vink R, Buller HR. The effects of unfractionated heparin on survival in patients with malignancy - a systematic review. Thromb Haemost 1999; 82: 1600-4.
10. Hettiarachchi RJ, Smorenburg SM, Ginsberg J, Levine M, Prins MH, Buller HR. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 1999; 82 947-52.
11. von Tempelhoff GF, Harenberg J, Niemann F, Hommel G, Kirkpatrick CJ, Heilmann L. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int J Oncol 2000; 16: 815-24.
12. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M for the CLOT Investigators. Low molecular weight heparin versus a Coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-53.
13. Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, Cetin M, Soyuer S. A randomized clinical trial of combination chemotheraphy with and without low molecular weight heparin in small cell lung cancer. J Thromb Haemost 2004; 2: 1266-71.
14. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M, Williamson RC. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer, the Fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22: 1944-8.
15. Klerk CPW, Smorenburg SM, Otten JMMB, Buller HR on Behalf of the MALT Study Group. Malignancy and low molecular weight-heparin therapy: the MALT trial. J Clin Oncol (in press).
16. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-CelignyP, Le Maignan C, Extra JM, Cottu P, Farge D. Comparison of low-molecular-weight-heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162: 1729-35.
17. Lee AY, Julian JA, Levine MN, Baker RI, Bodwen C, Kakkar AK, Prins M, Rickles FR, Gent M for the CLOT Investigators. Impact of dalteparin low-molecular-weight heparin (LMWH) on survival: results of a randomized trial in cancer patients with venous thromboembolism (VTE). Proc Am Soc Clin Oncol 2003; 22: 211 (Abstract 846).